Search Medical Condition
Please enter condition
Please choose location from dropdown

Metz cedex 03, France Clinical Trials

A listing of Metz cedex 03, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (73) clinical trials

Familial Dysglobulinemia

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no ...

Phase N/A

0.0 miles

Learn More »

Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following ...

Phase

0.0 miles

Learn More »

PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma

The occurence of a minor craniocerebral trauma in patients receiving vitamine K antagonist treatment leads to a high risk of bleeding. Current guidelines recommend to perform a CT scan, and, in case of intracranial bleeding, to reverse anticoagulation with concomitant administration of prothrombin complex concentrates (PCCs) and vitamin K. However, ...

Phase

0.0 miles

Learn More »

Metabolomic Analysis of Systemic Sclerosis

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years. The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of ...

Phase N/A

0.0 miles

Learn More »

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

Lung cancer is still the leading cause of cancer related-deaths worldwide, with an overall all-stage 5-year survival of approximately 17%. The primary treatment of early stage (I-IIIA) NSCLC is curative surgery. Although patients treated with curative surgery have a better prognosis, the 5-year survival for patients treated with surgery alone ...

Phase

0.0 miles

Learn More »

Prevention of Recurrence of Suicide Attempt by Adolescent by Sending SMS (MEDIACONNEX)

In industrialised countries, the incidence of SA among adolescents (ages 10-19 years old; 1) is estimated between 7% and 9% (2-3). Thirty percent of adolescents who have made a SA will do it again in the year. It appears that previous SA is "an independent and powerful predictor of futur ...

Phase N/A

0.0 miles

Learn More »

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Randomized, open-label, phase 3 trial in mCRPC patients aged 70 years. Treatment Arm A : cabazitaxel 25 mg/m on Day 1 of a 3-week cycle plus daily prednisone or Arm B: cabazitaxel 16 mg/m on Day 1 and Day 15 of a 4-week cycle plus daily prednisone. Treatment will be ...

Phase

0.0 miles

Learn More »

EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies

The primary endpoint is the rate of patients with tumors harboring a low level of genomic alteration (mutation, amplification or deletion) in genes (i.e. mutation, amplification, deletion) identified as causally implicated in cancer. A low level of genomic alteration is defined by the presence of less than the 5th quantile ...

Phase N/A

0.0 miles

Learn More »

HE4 as a Relapse Biomarker in Ovarian Cancers

HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of serum HE4 before surgery has been demonstrated to predict overall survival and its interest has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk patients. To date, no study shows ...

Phase N/A

0.0 miles

Learn More »

EPIPAGE2 Cohort Study Follow up at Five and a Half Years

Epipage 2 (epidemiologic study on small-for-gestational-age children) is a nationwide study implemented to improve our knowledge of the outcome of preterm children in France. This study was launched on March 28, 2011 and includes three groups of preterm children, all born before 35 weeks: extremely preterm infants (born between 22 ...

Phase N/A

0.0 miles

Learn More »